Lexaria Bioscience to Attend BIO International Convention Amid Record Business Development Interest
Lexaria Bioscience Corp. announces its attendance at the BIO International Convention in San Diego, highlighting a surge in partnership interest for its DehydraTECH drug delivery platform, which could lead to significant collaborations with pharmaceutical giants and biotech firms.
Lexaria Bioscience Corp. (NASDAQ: LEXX) is set to attend the BIO International Convention from June 22-25 in San Diego, CA, as part of an expanded business development program that has already generated record-high interest in its DehydraTECH drug delivery platform. The company's participation in last year's convention served as a catalyst for its current business development efforts, which are now yielding positive results.
"We are experiencing record-high levels of business development and collaboration interest in our DehydraTECH platform, even before the upcoming BIO conference," said Richard Christopher, CEO of Lexaria Bioscience. "New business relationships require intense energy and scientific evaluation from both prospective partners to discover the best fit possible. We are working tirelessly in this regard with the intent of generating positive developments that we can publicly discuss."
BIO is the largest convention of its kind, with over 20,000 attendees expected from the global pharmaceutical and biotechnology industries, as well as investors and finance professionals. The 2025 conference hosted over 66,000 partnering meetings. Lexaria has already begun reserving meetings and expects to be fully booked given strong industry interest in DehydraTECH.
Lexaria's multi-faceted BD program, quietly launched to inform prospective partners of DehydraTECH's benefits, has already generated collaborative discussions with a range of companies, from innovative small biotech developers to well-known global pharmaceutical giants. While many of these discussions are ongoing, the company continues to develop early-stage leads and intends to pursue only those that are in the best interests of its shareholders.
DehydraTECH is Lexaria's patented drug delivery formulation and processing platform technology that improves oral drug absorption, reduces side-effects, and enhances delivery across the blood-brain barrier. The company holds 65 granted patents and operates a licensed in-house research laboratory. For more information, visit Lexaria Bioscience's website.
The announcement comes as Lexaria's BD program continues to gain momentum, and the company expects to provide additional information when appropriate. The BIO convention represents a critical opportunity to build on these developments and potentially secure partnerships that could accelerate the commercialization of DehydraTECH.